Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/130120
Title: | A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases | Authors: | Zozaya González, María Neboa Arrizubieta Basterrechea, Maria Iciar Bollo, Elena Castellví, Iván Espín, Jaime Ortego, Norberto Poveda-Andrés, José Luis Rodríguez Portal, José Antonio Rivero, Agustín Marcos-Rodríguez, José Antonio Verde, Luis |
UNESCO Clasification: | 53 Ciencias económicas 531207 Sanidad |
Keywords: | Interstitial lung diseases Systemic sclerosis Pulmonary fibrosis Multi-criteria decision analysis |
Issue Date: | 2022 | Journal: | International Journal of Technology Assessment in Health Care | Abstract: | Objectives: Our aim was to assess the value of nintedanib for non-idiopathic progressive fibrosing interstitial lung disease (non-IPF PF-ILD) and systemic sclerosis-associated ILD (SSc-ILD) in the Spanish context, using a multi-criteria decision analysis (MCDA). Methods: Following an adaptation of the Evidence and Value: Impact on DEcision Making (EVIDEM) MCDA methodology, the estimated value of nintedanib was obtained by means of an additive linear model that combined individual weights (100-points distribution) of criteria with the individual scoring of nintedanib in each criterion for every indication, assigned by a multidisciplinary committee of twelve clinicians, patients, pharmacists, and decision-makers. To assess the reproducibility, an alternative weighting method was applied, as well as a re-test of weights and scores at a different moment of time. Results: The experts committee recognized nintedanib as an intervention with a positive value contribution in comparison to placebo for the treatment of non-IPF PF-ILD (0.50 0.16, on a scale from 1 to 1) and SSc-ILD (0.40 0.12), diseases which were considered as very severe and with high unmet needs. The drug was perceived as a treatment that provides an added therapeutic benefit for patients (0.06–0.07), given its proven clinical efficacy (0.05–0.06), slight improvements in patient-reported outcomes (0.01–0.02), and similar safety profile than placebo ( 0.04–0.00), which will likely be positioned as a recommended therapy in the next clinical practice guidelines updates. Conclusions: Under this increasingly used methodology, nintedanib has shown to provide a positive value estimate for non-IPF PF-ILD and SSc-ILD when compared to placebo in Spain. | URI: | http://hdl.handle.net/10553/130120 | ISSN: | 0266-4623 | DOI: | 10.1017/S0266462322000459 | Source: | International Journal of Technology Assessment in Health Care [ISSN 0266-4623], v. 38, n. 1, p. 1-10, (Julio 2022) |
Appears in Collections: | Artículos |
WEB OF SCIENCETM
Citations
2
checked on Mar 30, 2025
Page view(s)
90
checked on May 18, 2024
Download(s)
71
checked on May 18, 2024
Google ScholarTM
Check
Altmetric
Share
Export metadata
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.